Skip to main content
. 2017 Sep 14;8(61):103182–103206. doi: 10.18632/oncotarget.20892

Figure 10. High levels IL1β plus CXCL1 plus CCL2 plus S100A plus VEGF plus IL-8 correlates with adverse outcomes in breast cancer patients.

Figure 10

Kaplan Meier analysis of recurrence free survival (A), (n=3951), distant metastasis free survival (B), (n=1746), or overall survival (C), (n=1402) in IL1β plus CXCL1 plus CCL2 plus S100A plus VEGF plus IL-8 low expressing (black lines and numbers) vs. high expressing (red lines and numbers) breast cancer patients.